Status:
COMPLETED
A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants
Lead Sponsor:
Loxo Oncology, Inc.
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
21-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to learn about how food affects selpercatinib in healthy participants. The selpercatinib will be administered in fed and fasted states. Participation could last about...
Eligibility Criteria
Inclusion
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs and clinical laboratory tests.
Exclusion
- Have a history or presence of cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data.
Key Trial Info
Start Date :
April 19 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 22 2022
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT05324124
Start Date
April 19 2022
End Date
June 22 2022
Last Update
March 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lilly Centre for Clinical Pharmacology
Singapore, Singapore, 138623